PT-141 and naltrexone can interact when naltrexone is taken by mouth. Vyleesi's label says to “avoid use” with oral naltrexone products intended to treat alcohol or opioid addiction. Less naltrexone can reach the blood, which could undermine addiction treatment.
PT-141 is another name for bremelanotide, the drug in Vyleesi. The answer depends on which naltrexone product someone uses and why it was prescribed. A weight-management combination and a long-acting injection need separate consideration. The warning is not a reason to interrupt addiction care.
PT-141 and naltrexone: what happens to absorption?
Bremelanotide may slow gastric emptying, meaning food and medicine leave the stomach more slowly. That can change absorption: how much of a swallowed medicine reaches the blood, and how quickly.
The Vyleesi label's interaction-study graph, in section 12.3, shows lower naltrexone levels when the drugs were given together. Total exposure—the amount reaching the blood over time—was roughly 40% lower. The peak, or highest blood level, was about 60% lower. These are approximate readings from the graph, compared with oral naltrexone given alone.
Those figures describe drug levels. They do not mean addiction treatment becomes 40% less effective, or give a percentage chance of relapse.
The PT-141 sildenafil crossover study tested laboratory erection responses, a different question from naltrexone absorption.
A 2022 report in the Journal of Women's Health also identifies lowered naltrexone blood levels as an important interaction in bremelanotide's development program. This is a documented finding, rather than a concern inferred only from slow stomach emptying.
As of November 12, 2026, the day this article was written, the current FDA label reads “Revised: 10/2026.” It includes new human breast-milk transfer data. The instruction to avoid use with oral naltrexone for addiction treatment remains.
Why does addiction treatment matter here?
The oral naltrexone label covers treatment for alcohol dependence and blocking opioid effects as part of an addiction-care plan. Opioids are a drug group that includes morphine and fentanyl. Naltrexone blocks their effects; it is not an opioid itself.
The medicine may already be doing an important job. In a 1992 randomized trial in Archives of General Psychiatry, men receiving naltrexone alongside alcohol treatment reported less craving and fewer drinking days than those receiving placebo. A placebo is a comparison treatment without the active drug. That trial did not study bremelanotide.
Vyleesi's warning reflects the serious consequences if naltrexone treatment fails. It says to avoid the combination in this setting. It does not offer a workaround involving a few hours between medicines.
Any discussion about adding PT-141 needs to include the clinician managing the addiction treatment. Stopping or skipping naltrexone to make room for PT-141 could disrupt that care.
Does Contrave count as oral naltrexone?
Yes. Contrave's separate label identifies two ingredients: naltrexone and bupropion, an antidepressant. It is an extended-release tablet, meaning the ingredients are released over time. Its labeled use is long-term weight management alongside changes in food intake and physical activity.
That is a different indication—the reason a medicine is prescribed—from addiction treatment. Vyleesi's specific “avoid use” warning names oral naltrexone products intended for alcohol or opioid addiction. It does not establish that combining bremelanotide with Contrave is safe.
The absorption finding also does not establish how much weight someone would lose while taking both. Blood-level changes and weight outcomes are different questions.
The clinician needs the actual combination product, its release pattern and its prescribed dose. Contrave's own warnings also matter in that review, including its boxed warning about suicidal thoughts and behaviors and its warning about increases in blood pressure and heart rate. “It contains naltrexone” starts the discussion; it does not settle it.
What about injectable or low-dose naltrexone?
Vivitrol's label describes a long-acting naltrexone injection given into a muscle. It does not depend on a swallowed dose moving through the stomach. The oral interaction finding cannot be carried over as a percentage reduction for this injection.
That distinction does not prove the injectable combination is safe. It means the evidence about oral absorption answers a different question. Changing naltrexone products would be a separate treatment decision, not a simple way around the warning.
A prescription described as “low-dose naltrexone” also needs its own review. The Vyleesi label gives no lower naltrexone dose at which the interaction disappears. The reason for treatment and the actual preparation still matter.
What information changes the clinical review?
A medicine list needs more than the word “naltrexone.” The prescriber needs to know:
- The product name and all its active ingredients.
- Whether it is swallowed or injected, including any slow-release design.
- The prescribed dose and usual timing.
- Whether it treats addiction, weight concerns or another condition.
The same review needs the actual PT-141 preparation being considered, plus other medicines and the person's medical history. A name shared with a studied drug does not establish identical absorption or effects.
The PT-141 side-effects guide covers broader harms. The PT-141 and alcohol guide addresses drinking. Neither question replaces this specific check on naltrexone treatment.
How does Vyleesi's evidence relate to a compounded prescription?
The RECONNECT trials, published in Obstetrics & Gynecology in 2019, studied bremelanotide in women before menopause with distressing low sexual desire. Those trials do not establish that every PT-141 preparation can be combined safely with every naltrexone product.
PT-141 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A compounded medication is made for an individual prescription.
A licensed provider may still prescribe — that decision is between you and your doctor.
The Vyleesi prescribing-information guide explains the rest of the brand label. For this interaction, the key distinction is the exact naltrexone product and the care it supports.
The Medication Guide naming explainer distinguishes that document from Vyleesi's Patient Information and separate Instructions for Use.
How do the prescribers fit together?
At Promise, a licensed provider reviews every request, and not everyone qualifies. When naltrexone is already prescribed, that review needs to account for the existing treatment plan. The clinician managing that treatment has information a new prescriber may not have.
The prescriber sets any actual PT-141 dose and timing. For oral naltrexone used in addiction treatment, the labeled direction remains to avoid the combination. A proposed schedule cannot replace that warning.





